Sage's depression drug improves symptoms, but durability concerns sink shares
Reuters
Published Feb 16, 2022 08:20AM ET
Updated Feb 16, 2022 11:55AM ET
By Amruta Khandekar
(Reuters) - Sage Therapeutics Inc's drug helped improve depressive symptoms after three days in a late-stage study, but investor concerns over how long the treatment's effect would last sent the drug developer's shares down 17% on Wednesday.
In a study among 440 patients with major depressive disorder, the drug, zuranolone, taken along with an antidepressant also showed a statistically significant improvement in symptoms over a two-week period, the company and partner Biogen Inc (NASDAQ:BIIB) said on Wednesday.
Analysts, however, said the near-term durability of the oral drug would likely be the key to broader commercial success.
"The clinical benefit is modest and the effects are not durable," said Truist Securities analyst Joon Lee, adding that the regulatory process for the drug is likely to be "wrought with noise, controversy" over the next 12-18 months.
The trial results come after a separate late-stage trial in June raised similar concerns about how long the symptom improvement would last.
Major depressive disorder affects over 16 million American adults every year and is mainly treated with antidepressants, which could take up to six weeks to show effect.
Sage, which has a postpartum depression drug on the market, said it plans to file for U.S. approval of the drug this year. Sage signed a deal worth up to $1.5 billion with Biogen in 2020 to develop zuranolone along with another experimental drug.
While zuranolone showed greater reduction in symptoms than placebo after three days, the difference was still lower than Street expectations, Guggenheim analyst Yatin Suneja said.
But Suneja added that the drug remains approvable and he had expected its effect to wane over time as the company had decided to evaluate the results at day three for the main goal instead of at day fifteen as it had done in the June trial.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.